Clene Inc.'s latest quarterly filing reveals a second amendment to its senior secured convertible promissory notes, underscoring financial maneuvering in light of tight cash reserves. The company's proprietary electro-crystal-chemistry platform, which produces clean-surfaced catalytic nanocrystals, underpins its lead candidate CNM-Au8® targeting ALS, MS, and Parkinson’s disease. While clinical programs proceed with NIH-supported expanded access initiatives showing promise, the company faces notable liquidity pressures and regulatory hurdles amid a competitive CNS therapeutic landscape. Monitoring clinical milestones and capital raises will be critical to assessing Clene's pathway to commercialization.